Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
Ventus Therapeutics has raised $150K in total funding. The most recent round was Grant. The last funding was announced in April 2023.
Ventus Therapeutics's investors include Andreessen Horowitz, RA Capital Management, Cormorant Asset Management, Fonds de solidarité FTQ, Novo Nordisk.
Ventus Therapeutics is headquartered in Waltham, United States.
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
Ventus Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ventus Therapeutics — Funding & Investors." VCBacked, April 20, 2023, https://www.vcbacked.co/company/ventus-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Ventus Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/ventus-therapeutics
{{cite web |title=Ventus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ventus-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated